Key Generative Artificial Intelligence (AI) In Pharmaceutical Market Trend for 2025-2034: Advancements In Drug Discovery With Generative AI

What Is the Future Outlook for the Generative Artificial Intelligence (AI) In Pharmaceutical Market's Size and Growth Rate?
The market size of generative artificial intelligence (AI) within the pharmaceutical sector has experienced substantial growth recently. Its size is predicted to increase from $1.85 billion in 2024 to $2.43 billion in 2025, showing a compound annual growth rate (CAGR) of 31.3%. The noteworthy growth during the past period is due to several factors. These include advancements in computational prowess, the emergence of big data in the health and pharmaceutical sectors, enhanced investment in research and development, better data quality and integration, and the broadening scope of cloud computing.

Expectations are high for the generative artificial intelligence (AI) in the pharmaceutical market, as predictions suggest a spectacular growth trajectory over the coming years. By 2029, its worth is projected to surge to $7.16 billion, expanding at a compound annual growth rate (CAGR) of 31.0%. This predicted growth during the forecast period can be linked to various factors such as emphasis on early disease detection, supportive regulatory guidelines, heightened computational capabilities, escalation in drug development expenses, and the surge in data accessibility. Key trends for the forecast period incorporate the integration of blockchain and AI, advancement in data integration, enhanced disease diagnosis capabilities, automation in drug repurposing, as well as optimization of clinical trials in real-time.

What Is Stimulating Growth in the Generative Artificial Intelligence (AI) In Pharmaceutical Market?
The escalating emphasis on tailor-made medicine is projected to fuel the surge of generative artificial intelligence (AI) in the pharmaceutical sphere in the future. Customized medicine molds medical care to coincide with the distinct attributes, requirements, and choices of each individual, based on their genetic, environmental, and lifestyle factors. The growing attention towards personalized medicine is driven by advancements in genetic research and technology, facilitating a more targeted and effective treatment plan for each patient. Tailor-made medicine benefits from the use of generative AI in pharmacy to develop individualised drug interventions, thereby heightening the effectiveness of treatment and patient results. To illustrate, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, reported that the FDA had sanctioned 16 innovative personalized treatments for patients with rare diseases in 2023, an increase from six in 2022. Consequently, the rising emphasis on customized medicine is propelling the expansion of generative artificial intelligence (AI) in the pharmaceutical sector.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19474&type=smp

Which Key Market Leaders Are Driving Generative Artificial Intelligence (AI) In Pharmaceutical Industry Growth?
Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited

What Are the Emerging Trends in the Generative Artificial Intelligence (AI) In Pharmaceutical Industry?
Leading corporations in the pharmaceutical industry focusing on generative artificial intelligence (AI) are pioneering new offerings such as AI healthcare microservices to make drug discovery processes more efficient. AI healthcare microservices, deployed on the cloud and based on modular architecture, leverage artificial intelligence to enhance crucial healthcare activities like drug creation, medical imaging, and diagnostic treatments. As an example, Nvidia Corporation, a tech company based in the US, introduced generative AI microservices in March 2024. With optimized NIM AI models and workflow APIs, these microservices contribute to the development of applications designed for the cloud. They also offer specialized imaging, speech and natural language recognition, as well as digital biology features. Critical tools, including Parabricks, MONAI, NeMo, Riva, and Metropolis, are available as CUDA-X microservices, further improving workflows within genomics and drug discovery.

What Are the Main Segments in the Generative Artificial Intelligence (AI) In Pharmaceutical Market?
The generative artificial intelligence (AI) in pharmaceutical market covered in this report is segmented -

1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies
3) By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications

Subsegments:
1) By Small Molecule: Drug Discovery And Design, Lead Optimization For Small Molecule Compounds, Predictive Modeling For Pharmacokinetics And Toxicity, Virtual Screening Of Compound Libraries, Personalized Medicine Approaches For Small Molecule Therapies
2) By Large Molecule: Biologics Discovery And Development, Monoclonal Antibody Design, Protein Engineering And Optimization, Vaccine Development And Optimization, Predictive Models For Biopharmaceutical Efficacy And Safety.

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/generative-artificial-intelligence-ai-in-pharmaceutical-global-market-report

Which Geographic Area Leads the Generative Artificial Intelligence (AI) In Pharmaceutical Market?
North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2024. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Is Covered In The Generative Artificial Intelligence (AI) In Pharmaceutical Global Market Report?

- Market Size Analysis: Analyze the Generative Artificial Intelligence (AI) In Pharmaceutical Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Generative Artificial Intelligence (AI) In Pharmaceutical Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Generative Artificial Intelligence (AI) In Pharmaceutical Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Generative Artificial Intelligence (AI) In Pharmaceutical Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19474

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.